Compare DOMO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | VNDA |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.0M | 289.0M |
| IPO Year | 2018 | 2006 |
| Metric | DOMO | VNDA |
|---|---|---|
| Price | $8.91 | $7.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $14.38 | $14.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 12-04-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,002,000.00 | $212,074,000.00 |
| Revenue This Year | $2.32 | $12.01 |
| Revenue Next Year | $2.72 | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $6.01 | $3.81 |
| 52 Week High | $18.49 | $7.05 |
| Indicator | DOMO | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 33.16 | 70.91 |
| Support Level | $8.55 | $6.15 |
| Resistance Level | $8.97 | $7.05 |
| Average True Range (ATR) | 0.54 | 0.47 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 15.03 | 100.00 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.